ACTUATE THERAPEUTICS, INC.

Consensus Actuate Therapeutics, Inc.

Stocks

ACTU

US0050831009

Biotechnology & Medical Research

Market Closed - Nasdaq 00:00:00 19/09/2026 +04			5-day change	1st Jan Change
0.9812 ^USD	-1.41%		-8.30%	-83.97%

09-09	Actuate Therapeutics Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with Ras Inhibitors Zoldonrasib and Daraxonrasib	CI
08-15	Actuate Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Evolution of the Average Target: Actuate Therapeutics, Inc.

Evolution of the Target Price: Actuate Therapeutics, Inc.

Changes in Analyst Recommendations: Actuate Therapeutics, Inc.

431539109c1aba6.TgsG6hKk3pd9BDIEX69UeHVtzKdEdadk0N8jCEjGZDo.OkdQuXnC6eFMbn9vCNYECkYhv_8iPe8xpphCZiKfJnwtcVyvY_yzozFWZw~dfc6b1caf8a4b65019cd09c139b0b12e

Analysts' recommendations: Actuate Therapeutics, Inc.

04-15	B. Riley Cuts Actuate Therapeutics Price Target to $8 From $20, Maintains Buy Rating	MT
26/08/25	B. Riley Initiates Actuate Therapeutics With Buy Rating, $20 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ACTUATE THERAPEUTICS, INC.					+1,090.72%
	WUXI APPTEC CO., LTD.					+16.92%
	ARGENX SE					+17.91%
	WUXI BIOLOGICS (CAYMAN) INC.					+15.47%
	INSMED INCORPORATED					+66.29%
	BIONTECH SE					+23.62%
	GENMAB A/S					+8.57%
	PHARMAESSENTIA CORPORATION					+18.41%
	EXELIXIS, INC.					-8.01%
	SUMMIT THERAPEUTICS INC.					+62.99%
	Average					+131.29%
	Weighted average by Cap.					+22.92%

See all sector performances

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

BUY

Number of Analysts

3

Last Close Price

0.9812USD

Average target price

11.68USD

Spread / Average Target

+1,090.72%

High Price Target

15.05USD

Spread / Highest target

+1,433.84%

Low Price Target

8.000USD

Spread / Lowest Target

+715.33%

Analyst Consensus Detail

Consensus revision (last 18 months)

Stock Market
Stocks
ACTU Stock
Consensus Actuate Therapeutics, Inc.

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!

SEIZE THE OFFER!

×